# US 2022/0089681 A1 · Methods for modulating an immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0089681 A1
- Document ID: US20220089681A1
- Status: Published application
- Kind: A1
- Application number: 17/381,858
- Filed: 2021-07-21
- Published: 2022-03-24
- Earliest claimed: 2017-03-15
- Assignees: Cue Biopharma, Inc.
- Applicants: Cue Biopharma, Inc.
- Inventors: Ronald D. Seidel, III; Rodolfo J. Chaparro
- Web page: https://patentgrep.com/patent/US20220089681A1

## CPC

- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/2013: {IL-2}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/644: {Transferrin, e.g. a lactoferrin or ovotransferrin}
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/55: IL-2
- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 2039/505: {comprising antibodies}
- C07K 2317/524: CH2 domain
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C12N 2770/36143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.

## Claims

### Claim at position 1

-54. (canceled)

### Claim 55

A method of treating an individual having a cancer that expresses an HPV16 E7 antigen, the method comprising administering to the individual a combination of (i) an effective amount of an immune checkpoint inhibitor that targets PD-1, and (ii) an effective amount of a protein that is a homodimer of two multimeric polypeptides, wherein each multimeric polypeptide comprises:
a) a first polypeptide comprising from N-terminus to C-terminus:
i) an HPV16 E7 epitope comprising amino acid sequence YMLDLQPETT (SEQ ID NO:77);
ii) a linker comprising amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO:207); and
iii) a β2-microglobulin (β2M) polypeptide comprising the amino acid sequence set forth in SEQ ID NO:48; and
b) a second polypeptide comprising:
i) two copies of an IL-2 polypeptide, each copy comprising the amino acid sequence set forth in SEQ ID NO:49;
ii) a second MHC polypeptide, wherein the second MHC polypeptide is an MHC class I heavy chain polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:50; and
iii) an immunoglobulin (Ig) Fc polypeptide, and
wherein the multimeric polypeptides are joined to each other by one or more disulfide bonds that join the Ig Fc polypeptide of one multimeric polypeptide to the Ig Fc polypeptide of the other multimeric polypeptide, and
wherein the immune checkpoint inhibitor and the protein are administered at the same time or at different times.

### Claim 56 (depends on 55)

A method of treating according to claim 55,
wherein the Ig Fc polypeptide comprises an amino acid sequence having at least about 95% amino acid sequence identity to SEQ ID NO:21, and wherein the Ig Fc polypeptide comprises an L14A substitution and an LISA substitution based on the amino acid numbering depicted in SEQ ID NO:44;
wherein the first and second polypeptides are covalently linked to one another via a disulfide bond between the Cys residue at amino acid 12 of the β2M polypeptide and the Cys residue at amino acid 236 of the class I MHC heavy chain polypeptide, and
wherein the second polypeptide comprises a peptide linker between one or more of:
a) a first copy of the IL-2 polypeptide and a second copy of the IL-2 polypeptide;
b) one of the two copies of the IL-2 polypeptide and the MHC class I heavy chain polypeptide; and
c) the MHC class I heavy chain polypeptide and the Ig Fc polypeptide.

### Claim 57 (depends on 55)

A method according to claim 55, wherein the cancer is a head and neck cancer.

### Claim 58 (depends on 56)

A method according to claim 56, wherein the cancer is a head and neck cancer.

### Claim 59 (depends on 55)

A method according to claim 55, wherein the cancer is a cervical cancer, or a genitoanal cancer.

### Claim 60 (depends on 56)

A method according to claim 56, wherein the cancer is a cervical cancer, or a genitoanal cancer.

### Claim 61 (depends on 55)

A method according to claim 55, wherein the individual has become refractory to a prior treatment for the cancer or has failed to respond to a prior treatment for the cancer.

### Claim 62 (depends on 56)

A method according to claim 56, wherein the individual has become refractory to a prior treatment for the cancer or has failed to respond to a prior treatment for the cancer.

### Claim 63 (depends on 55)

A method according to claim 55, wherein the protein is administered in an amount of administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.

### Claim 64 (depends on 56)

A method according to claim 56, wherein the protein is administered in an amount of administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.

### Claim 65 (depends on 57)

A method according to claim 57, wherein the protein is administered in an amount of administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.

### Claim 66 (depends on 58)

A method according to claim 58, wherein the protein is administered in an amount of administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.

### Claim 67 (depends on 59)

A method according to claim 59, wherein the protein is administered in an amount of administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.

### Claim 68 (depends on 60)

A method according to claim 60, wherein the protein is administered in an amount of administered in an amount of from about 1 mg/kg to about 5 mg/kg of body weight.
